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Aim: Prevention of medication-related osteonecrosis of the jaw (MRONJ) in patients with
osteoporosis requires the cooperation of physicians and dentists. We investigated the
knowledge, experience, and behaviour related to medical and dental cooperation for
MRONJ prevention in patients with osteoporosis between physicians and dentists practis-
ing in the Shiga prefecture. Materials and methods: We conducted a cross-sectional study
to investigate the cooperation between practising physicians and dentists for preventing
osteonecrosis of the jaw (ONJ) in patients with osteoporosis using 2 separate question-
naires from July 28, 2018, to February 3, 2019, in Shiga prefecture, Japan. Results: Of 461
dentists who were sent the questionnaires at their dental clinics, 307 (67%) responded via
fax. Of 846 physicians whowere sent the questionnaire at their clinics, 378 (45%) responded
via fax. Of these, 268 (32%) were finally analysed because 110 (13%) physicians had never
treated patients with osteoporosis; 50% dentists and 24% physicians were familiar with the
MRONJ position paper in Japan, and 39% dentists and 9% physicians had encountered
MRONJ in their clinical practice. A total of 30% physicians had requested oral health care
by a dentist before administering bone-modifying agents (BMA) therapy. The knowledge
and experience of MRONJ differed between doctors and dentists. Conclusion: The behav-
iour of doctors and dentists was insufficient to enable medical and dental cooperation for
the prevention of MRONJ in patients with osteoporosis. The lack of cooperation between
physicians and dentists during osteoporosis treatment in the Shiga prefecture in Japan is
documented in this study.
 2020 The Authors. Published by Elsevier Inc on behalf of FDI World Dental Federation.
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Bone-modifying agents (BMA) such as bisphosphonate and
denosumab are widely and safely used as first-line therapy
for osteoporosis; they reduce the bone loss and risk of mor-
bidity and mortality resulting from osteoporotic fractures.1
However, after Marx et al2 and Ruggiero et al3 reported
osteonecrosis of the jaw (ONJ), it has been known as an
intractable, although rare, complication associated with the
use of intravenous and oral bisphosphonates. Although thisreport was published more than 15 years previously, there
is no standardised therapeutic protocol for medication-
related osteonecrosis of the jaw (MRONJ). MRONJ prevention
remains the main goal that can be achieved with treatment
of the dental lesions using a multidisciplinary approach
before initiating antiabsorption therapy, followed by contin-
uous monitoring of the dental disease.4 Because MRONJ
treatment is generally difficult, no optimal therapeutic
strategy has been established.5 The Japanese position paper
that was revised in 2016 states that the key factor in pre-
venting MRONJ in patients with osteoporosis is the close
collaboration between dentists and physicians.6 After the
publication of the position paper, educational activities,
such as lectures, were held in Japan in accordance with the
contents.
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physicians in 2015 indicated that 62% did not require den-
tists to perform oral health care before the administration
of BMA, and 72% reported no cooperation between physi-
cians and dentists.7 These results suggest that lack of
communication and interaction between physicians and
dentists in the treatment of patients with osteoporosis
may be responsible for the ongoing increase in the inci-
dence of MRONJ in Japan.6
Previous studies were performed on physicians of the Jap-
anese Osteoporosis Society who specialised in the treatment
of osteoporosis.7,8 Few studies have investigated the preven-
tion of MRONJ in patients with osteoporosis with both physi-
cians and dentists in the same area. The knowledge and
experience of physicians and dentists influence their clinical
practice behaviour. Medical and dental cooperation is estab-
lished by their actions. Evaluation of the knowledge and
experience of physicians and dentists regarding MRONJ
prevention in patients with osteoporosis will assist in under-
standing the issues hindering cooperation between physi-
cians and dentists. Therefore, the current study investigated
the knowledge, experience, and behaviour related to coopera-
tion between physicians and dentists treating MRONJ in
patients with osteoporosis in the Shiga prefecture.Methods
Questionnaire-based survey
We conducted a cross-sectional study to investigate the coop-
eration between practising physicians and dentists for pre-
venting ONJ in patients with osteoporosis using 2 separate
questionnaires. We explained the main points of the survey
at the regular meetings of the medical association and den-
tists association and obtained consent for the survey. From
July 28, 2018, to February 3, 2019, the anonymous, self
administered, structured questionnaire was sent to 846 clin-
ics belonging to 9 local medical associations and 461 clinics
belonging to 7 local dental associations in the Shiga prefec-
ture in Japan. Physicians who had never treated patients with
osteoporosis were excluded (eg, specialty in paediatrics, oph-
thalmology, otolaryngology, dermatology, plastic surgery,
psychiatry). This survey targeted dentists who are engaged in
general dentistry. Dentists specialising in oral maxillofacial
surgery and paediatric dentistry were excluded. The survey
did not require the physicians and dentists to provide any
personal information, and subject consent was implied if
they provided the completed questionnaire. The question-
naire included the following 7 important clinical queries for
each physician and dentist:Queries for dentist (QD)
QD-1. Do you knowmedication-related ONJ (MRONJ)?
QD-2. Do you know the latest MRONJ position paper pub-
lished in Japan?
QD-3. Have you had any personal experience with MRONJ
during your practice?QD-4. Have you ever had any problems during the treatment
of patients who are taking BMA? (multiple-choice questions)
(1) No
(2) Explain the patients about MRONJ
(3) Indications for invasive procedures, such as tooth extraction
(4) Discontinuation of BMA during dental treatment
(5) Other
QD-5. Have patients ever visited your dental clinic under the
instructions of their doctor before BMA therapy?
QD-6. Have you ever consulted about patients during BMA
therapy with their doctor?
QD-7. Do you have good cooperation with medical profes-
sionals during the treatment of osteoporosis with BMA
therapy?
Queries for physician (QP)
QP-1. Do you knowmedication-related ONJ (MRONJ)?
QP-2. Do you know the latest MRONJ position paper published
in Japan?
QP-3. Have you had any personal experience with MRONJ dur-
ing your practice?
QP-4. Are you explaining about MRONJ while prescribing BMA
to osteoporotic patients?
QP-5. Have you requested oral health care by a dentist before
BMA therapy?
QP-6. Have you ever been consulted by a dentist about a
patient during BMA therapy?
QP-7. Do you have good cooperation with dentists during the
treatment of osteoporosis with BMA therapy?
Frequency distributions and descriptive statistics were
generated for all the study variables. Fisher exact test was
performed to detect significant associations among cate-
gorical variables. This study did not require ethics
approval from the Shiga University of Medical Science
ethics committee because it did not involve individual
data or interventions in the protocol and results. This
questionnaire survey was conducted as per the principles
of the Declaration of Helsinki and the ethical guidelines of
epidemiological research of the Ministry of Health, Labor
and Welfare in Japan.Results
Respondents
Of the 461 dentists who were sent the questionnaire at
their dental clinics, 307 (67%) responded via fax. Of the
846 physicians who were sent the questionnaire at their
clinics, 378 (45%) responded via fax. Finally, 268 (32%) sub-
jects enrolled in the study after excluding 110 (13%) physi-
cians who had never treated patients with osteoporosis.
Of the 268, 52 respondents (32%) had worked in the ortho-
paedics field as specialists who prescribe osteoporotic
medicine in Japan.
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The results are divided into knowledge and experience, col-
laboration, and other. For the query with multiple-choice
responses (QD-4), the number of responses and the total
number of respondents were not matched. The results of
each query for dentists and physicians are shown here.
Knowledge and experience regarding MRONJ
Knowledge of MRONJ (QD-1, 2 and QP-1, 2). The same ques-
tions were asked to dentists and physicians about their
knowledge of MRONJ.
QD-1, QP-1: Do you knowmedication-related ONJ (MRONJ)?
A total of 296 dentists (96%) and 253 physicians (94%) knew
about MRONJ (Figures 1 and 2).
QD-2, QP-2: Do you know the latest MRONJ position paper
published in Japan?
Among dentists, 153 (50%) were familiar with the position
paper, whereas 151 (49%) were unaware. Three (1%) subjects
did not respond. Among the physicians, 65 (24%) were familiar
with the position paper and 198 (74%) were unfamiliar. Five (2%)
subjects did not respond. The proportion of respondents who
knew about the latest position paper of the Japanese Society forFig. 1 –Dentists’ responses to questions abouBone and Mineral Research (JSBMR) was significantly lower for
physicians than for dentists (P < .01) (Figures 1 and 2).
Experience of MRONJ (QD-3, QP-3). The same question was
presented to dentists and physicians about their experience
of MRONJ.
QD-3, QP-3: Have you had personal experience with
MRONJ in your practice?
Among dentists, 120 (39%) had treated patients with MRONJ
during their practice, whereas 180 (59%) had never treated a
patient with MRONJ. Seven (2%) subjects did not respond.
Among the physicians, 25 (9%) reported having treated a patient
with MRONJ during their practice, and 240 respondents (90%)
had never treated a patient with MRONJ. Three (1%) subjects did
not respond. The proportion of physicians who had a personal
experience with MRONJ was significantly lower than the pro-
portion of dentists who had (P < .01) (Figures 1 and 2).Behaviour for patients with osteoporosis related to medical and
dental cooperation
Explanation to patients about MRONJ by physicians (QP-4). Tag-
gedPQP-4: When you prescribe BMA to osteoporotic patients, are
you explaining about MRONJ?t MRONJ (QD-1, 2, 3, 5, 6, and 7) (n = 307).
Fig. 2 – Physicians’ responses to questions about MRONJ (QP-1, 2, 3, 4, 5, 6, and 7) (n = 268).
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to their patients, whereas 102 (38%) did not provide any
such explanation. Nine (3%) subjects did not respond
(Figure 2).
Problems for dentists in treating patients during BMA therapy
(QD-4). QD-4: Have you ever had any problems with the
treatment of patients who are taking BMA? (multiple-choice
questions)
Fifty-seven respondents (19%) had never experienced
problems with the treatment of patients who were taking
BMA, and 250 respondents (81%) reported having faced
challenges in such cases. There are 461 answers in total
regarding the problems for dentists in treating patients
during BMA therapy in this multiple-answer question. Of
these 461 answers, 104 (23%) reported that they found it
challenging to explain MRONJ to patients; 199 (43%) report-
edly found it difficult to understand the indications for
invasive procedures, such as tooth extraction; 147 (32%)
stated having issues while making a decision about dis-
continuation of BMA during dental treatment; and 11 (2%)
reported other issues (Figure 3).Consultation by dentists before BMA therapy (QD-5, QP-5). Tag-
gedPQD-5: Have patients ever visited your dental clinic under the
instruction of their doctor before BMA therapy?
Among dentists, 215 (70%) reported that they had experi-
ence of referrals before BMA therapy, while 90 respondents
(29%) had no such experience. Two (1%) subjects did not
respond (Figure 1).
QP-5: Have you requested oral health care by a dentist
before BMA therapy?
Among physicians, 80 (30%) had, at some point, requested
oral health care by a dentist before they administered BMA
therapy, while 179 respondents (67%) had never referred their
patient to a dentist for such care. Nine (3%) subjects did not
respond (Figure 2).
Consultation to physicians during BMA therapy (QD-6, QP-6). Tag-
gedPQD-6: Have you ever consulted about patients during BMA
therapy with their doctor?
Among dentists, 170 (55%) had consulted a physician
about patients during BMA therapy with their doctor,
whereas 129 (42%) had never consulted. Eight (3%) subjects
did not respond (Figure 1).
Fig. 3 –Dentists’ responses to QD-4 (multiple-choice question).
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patient during BMA therapy?
Among physicians, 138 (51%) had been consulted by a
dentist about a patient during BMA therapy, while 128 (48%)
had never been consulted. Two (1%) subjects did not respond
(Figure 2). The percentage of dentists who had consulted a
physician was similar to the percentage of physicians who
reported having been consulted by a dentist during BMA
therapy.
Cooperation for the prevention of MRONJ
Cooperation during BMA therapy (QD-7, QP-7). QD-7: Do you
have good cooperation with medical professionals during the
treatment of osteoporosis with BMA therapy?
Among dentists, 74 (24%) cooperated with medical profes-
sionals during the treatment of osteoporosis with BMA ther-
apy, whereas 220 (72%) did not report having cooperated.
Thirteen (4%) subjects did not respond (Figure 1).
QP-7: Do you have good cooperation with dentists during
the treatment of osteoporosis with BMA therapy?
Among physicians, 62 (23%) cooperated with a dentist dur-
ing the treatment of osteoporosis with BMA therapy, while
195 (73%) did not report such cooperation. Eleven (4%) sub-
jects did not respond (Figure 2).
More than 70% of the respondents, both dentists and
physicians, reported that they had experience of good cooper-
ation with the other during BMA therapy.Discussion
The prevention of MRONJ in patients with osteoporosis
requires the cooperation of physicians and dentists.6 A
questionnaire-based survey was conducted for both physi-
cians and dentists practising in the Shiga prefecture in
terms of the knowledge, experience, and behaviour related
to medical and dental cooperation for the prevention ofMRONJ in osteoporosis patients. To our knowledge, our
report is the first to survey both medical and dental profes-
sionals in Japanese concerning this issue. We made 2
important clinical observations. First, the knowledge and
experience regarding MRONJ differed between physicians
and dentists. Second, the behaviour of doctors and den-
tists did not allow for sufficient cooperation between
physicians and dentists to prevent MRONJ in patients with
osteoporosis.
First, the knowledge and experience of MRONJ differed
between physicians and dentists. MRONJ was first
reported more than 15 years previously, and in this survey,
almost all physicians and dentists knew about MRONJ. Fol-
lowing the publication of the position paper by the Ameri-
can Association of Oral and Maxillofacial Surgeons
(AAOMS) in 2006, many position papers have been pub-
lished and revised, providing information regarding the
most recent cases of diagnosis and treatment. Even
though educational activities, such as lectures, were held
in Japan in accordance with the contents after the MRONJ
position paper that was published in 2016 in Japan,6 only
50% of the dentists and 25% of the physicians knew about
it. Neither physicians nor dentists are sufficiently updated
in their knowledge about MRONJ. Physicians were less
updated than dentists. Dentists may be more conscious
than physicians about updating their knowledge regarding
MRONJ because dentists are at risk of being directly
involved in its development. To provide good treatment
for patients with osteoporosis, it is important that both
physicians and dentists have the same basis of knowledge
and perform each treatment with common awareness.
However, the results of this study did not reflect such
standardised knowledge and treatment.
Furthermore, physicians and dentists differed greatly in
their experience of ONJ in patients with osteoporosis. This
survey was conducted in a single region; therefore, the
number of patients with osteoporosis who developed
MRONJ was considered to be the same. However, there
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between physicians and dentists, with the physician popu-
lation being larger than the dentist population. Diagnosis
and treatment of MRONJ is mainly performed by dentists.
It is suggested that the dentists may not report to physi-
cians the development of MRONJ in their patients. Dentists
need to inform physicians regarding the onset of MRONJ in
their patients because physicians may then develop a
greater awareness regarding MRONJ prevention in
patients. Another possibility is that the dentist informed
the physicians about the diagnosis, and it did not mature
into an action. In that case, it is necessary to educate
them to make them more aware of MRONJ.
Second, the behaviour of doctors and dentists was not
compatible with cooperation between physicians and den-
tists for preventing MRONJ in patients with osteoporosis.
Explanations of MRONJ by physicians would encourage
patients with osteoporosis to pay attention to their oral
health. However, physicians do not provide sufficient expla-
nation regarding MRONJ to patients. We found that the types
of difficulties that dentists experienced while examining
patients with osteoporosis were different from those that
they experienced while examining other patients. One such
challenge is the difficulty of explaining MRONJ to patients
experienced by dentist may have arisen from physicians not
educating the patient about MRONJ. Most dentists found it
difficult to understand the indication for surgical procedures,
such as tooth extraction in patients at risk of developing
MRONJ. Dentists also found it difficult to decide whether to
withdraw BMA before the surgery because this issue is still
under discussion.6 Prescribing physicians need to better
understand the challenges faced by dentists in treating
patients with osteoporosis. In addition, 67% of the physicians
had never referred a patient for dental treatment before their
therapy. This finding was reported at 62% in the previous
report,7 and the results of this study are similar to those,
indicating that many physicians still do not refer their
patients to dentists before initiating antiabsorption therapy.
More awareness in oral health and explanation about MRONJ
for patients with osteoporosis are needed for physicians to
facilitate a change in their scope of practice. In this study,
only 25% of the physicians and dentists did not consult or
refer their patients to each other to prevent MRONJ. Further
cooperation between physicians and dentists is needed to
prevent MRONJ in this region. If dentists and physicians
coordinate and communicate more closely with each other,
MRONJ could be prevented in patients with osteoporosis,
enabling uninterrupted BMA therapy.
Certain limitations of this study should be acknowl-
edged. First, this study may have a selection bias because
of the low proportion of respondents. Second, a potential
limitation is that this study used self-reported data of par-
ticipants that may contain inaccuracies. A further possible
limitation of the study is that it may not be representative
of all dentists and physicians in Japan because it was lim-
ited to a certain region of Japan. However, considering that
previous studies have reported similar findings for physi-
cians, the present results may indicate the current status
of medical and dental collaboration in the treatment of
osteoporosis in Japan.Conclusion
In conclusion, the present study highlighted the ill-matched
situation between dentists and physicians in the knowledge
and experience of MRONJ. Neither physicians nor dentists
were updated regarding the advancements in the diagnosis
and treatment of MRONJ. Physicians had less experience with
MRONJ than dentists. It is suggested that dentists did not
report to the physician about the development of jaw osteo-
necrosis in their patients. For their part, physicians did not
provide the necessary information about MRONJ to their
patients and failed to refer their patient for dental treatment
before initiating antiabsorption therapy. Thus, the lack of
cooperation between physicians and dentists during osteopo-
rosis treatment in the Shiga prefecture in Japan is docu-
mented in the present study.Author contributions
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